跳至主要内容
临床试验/CTRI/2024/06/068713
CTRI/2024/06/068713尚未招募不适用

Real-World Treatment Patterns and Clinical Outcomes Among Patients with Urothelial Carcinoma (UC) in India

Pfizer Products India Private Limited8 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2024年6月20日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
300
试验地点
8
主要终点
Overall Survival (OS) outcomes of patients with High-risk NMIBC and mUC treated at tertiary care institutions in India. (The percentage of people in the study who are still alive for a certain period of time after they were diagnosed with or started treatment for cancer).

研究概览

简要总结

Notification for the conduct of Non- interventional study- ‘Real-World Treatment Patterns and Clinical outcomes among Patients with Urothelial Carcinoma (UC) in India’, Protocol Number B8011015, Version 1.0 Dated 22-Aug-2023.

研究设计

研究类型
Observational

入排标准

年龄范围
18.00 Year(s) 至 99.00 Year(s)(—)
性别
All

入选标准

  • All patients of high risk NMIBC who both initiated treatment and/or diagnosed Jan 2023 onwards.
  • All patients of metastatic urothelial carcinoma who initiated treatment and/or diagnosed Jan 2023 onwards.
  • Aged at least 18 years upon diagnosis.

排除标准

  • Previously enrolled in an interventional trial related to High-risk NMIBC or mUC.

结局指标

主要结局

Overall Survival (OS) outcomes of patients with High-risk NMIBC and mUC treated at tertiary care institutions in India. (The percentage of people in the study who are still alive for a certain period of time after they were diagnosed with or started treatment for cancer).

时间窗: 18 Months

次要结局

  • To understand the baseline characteristics of the(patient/disease status)

研究者

发起方
Pfizer Products India Private Limited
申办方类型
Pharmaceutical industry-Indian
责任方
Principal Investigator
主要研究者

Dr Antara Chaudhri

Pfizer Products India Private Limited

研究点 (8)

Loading locations...

相似试验